NEWYORK, NY — The Michael J. Fox Foundation awarded a total of about $2.7 million to four industry research teams for pre-clinical research on potential new treatments for Parkinson’s disease.
The funding was awarded under the Foundation’s Therapeutics Development Initiative. This program, first launched in 2006, supports and bolsters industry-focused efforts on Parkinson’s research. TDI is part of MJFF’s focus on ‘de-risking’ preclinical PD research for biotech and pharmaceutical companies, thus expanding and catalyzing industry investments in Parkinson’s drug development. By adding MJFF resources to companies’ own, the Foundation aims to make Parkinson’s therapies a more attractive bet and help to push research further along the pipeline.
The funded projects are listed below. Full information, including grant abstracts and researcher bios, is available on the Foundation’s Web site — www.michaeljfox.org.
Cerebrospinal Fluid (CSF) Biomarkers of Microtubule-mediated Axonal Transport for Monitoring of Disease Progression and Therapeutics Interventions in Parkinson’s Disease
Patrizia Fanara, PhD, KineMed, Inc.
Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson’s Disease
Vincent Allen Florio, PhD, Omeros Corporation
Development of ER-beta Agonists for the Treatment of Parkinson’s Disease
Roger Olsson, PhD, and Krista McFarland, PhD, Acadia Pharmaceuticals, Inc.
Multiphosphatase Inhibitors as Therapeutics for Parkinson’s Disease
Arnon Rosenthal, PhD, and Franz F. Hefti, PhD, ShanaRX